Vikram Purohit
Stock Analyst at Morgan Stanley
(0.72)
# 3,733
Out of 4,734 analysts
170
Total ratings
24.19%
Success rate
-15.57%
Average return
Main Sectors:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $8.40 | +316.67% | 2 | Dec 11, 2024 | |
| INCY Incyte | Maintains: Equal-Weight | $64 → $69 | $73.47 | -6.08% | 23 | Oct 30, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.41 | +104.08% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $21.80 | +42.20% | 2 | Sep 11, 2024 | |
| SLRN Acelyrin | Maintains: Equal-Weight | $13 → $6 | $1.99 | +201.51% | 7 | Aug 19, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $59 → $64 | $55.94 | +14.41% | 6 | Aug 7, 2024 | |
| ABSI Absci | Initiates: Overweight | $7 | $3.22 | +117.39% | 1 | Jul 3, 2024 | |
| ASND Ascendis Pharma | Maintains: Equal-Weight | $116 → $140 | $131.06 | +6.82% | 18 | May 16, 2024 | |
| AXSM Axsome Therapeutics | Upgrades: Overweight | $90 → $115 | $96.18 | +19.57% | 18 | Apr 29, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $6.37 | +151.18% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $3.64 | +724.18% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $22 | $6.94 | +217.00% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $13.08 | -23.55% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $2.08 | +188.46% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $7.57 | +454.82% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $6.88 | +59.88% | 1 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $23 | $2.04 | +1,002.94% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $43.70 | -6.18% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $19.61 | +103.98% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $1.79 | +626.26% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $21.33 | +78.15% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $12.61 | +58.60% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $9.15 | +9.29% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $7 | $13.56 | -48.38% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $2.37 | +828.27% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $4.52 | +342.48% | 2 | Aug 5, 2020 |
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $8.40
Upside: +316.67%
Incyte
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $64 → $69
Current: $73.47
Upside: -6.08%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.41
Upside: +104.08%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $21.80
Upside: +42.20%
Acelyrin
Aug 19, 2024
Maintains: Equal-Weight
Price Target: $13 → $6
Current: $1.99
Upside: +201.51%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Overweight
Price Target: $59 → $64
Current: $55.94
Upside: +14.41%
Absci
Jul 3, 2024
Initiates: Overweight
Price Target: $7
Current: $3.22
Upside: +117.39%
Ascendis Pharma
May 16, 2024
Maintains: Equal-Weight
Price Target: $116 → $140
Current: $131.06
Upside: +6.82%
Axsome Therapeutics
Apr 29, 2024
Upgrades: Overweight
Price Target: $90 → $115
Current: $96.18
Upside: +19.57%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $6.37
Upside: +151.18%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $3.64
Upside: +724.18%
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $6.94
Upside: +217.00%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $13.08
Upside: -23.55%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $2.08
Upside: +188.46%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $7.57
Upside: +454.82%
Jul 13, 2023
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $6.88
Upside: +59.88%
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $2.04
Upside: +1,002.94%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $43.70
Upside: -6.18%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $19.61
Upside: +103.98%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $1.79
Upside: +626.26%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $21.33
Upside: +78.15%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $12.61
Upside: +58.60%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $9.15
Upside: +9.29%
Dec 10, 2021
Downgrades: Underweight
Price Target: $18 → $7
Current: $13.56
Upside: -48.38%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $2.37
Upside: +828.27%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $4.52
Upside: +342.48%